Skip to main content
. 2020 Jan-Mar;13(1):68–74. doi: 10.25122/jml-2019-0076

Table 1:

Clinical and demographic characteristics of patients with compensated liver cirrhosis and hepatitis C virus infection.

Parameter Percentage (%) or average (range)
Male gender 49.2%
IFN Pre-treated patients (relapsers/non-responders) 67.3% (39.1%/57.3%)
Co-morbidities 37.3%
HBs-Ag positive patients 34/2068 (1.6%)
Class A Child Pugh score (6 points) 216/2068 (10.44%)
Class B Child Pugh score (7 points) 11/2068 (0.5%)
BMI 27.2 (16.84÷44.9)
Age 60 (25÷82) years
ALT 88 (19 ÷ 604) IU/ml
AST 77 (20 ÷ 431) IU/ml
Platelets 133000/ mm3 (12000 ÷ 650000)
Total bilirubin 0,9 (0,1 ÷ 3.61) mg/dl
INR 1.11 (0.34 ÷3)
MELD 8.09 (6 ÷ 22)
e Cl Cr 98 (15 ÷ 347) ml/min
Blood glucose 105 (60 ÷ 454) mg/dl
Severe non-alcoholic steatohepatitis* 50.1%
Severe necroinflammation (grade 3 or 4 by Fibromax)* 67.5%

* estimated through FibroMax™ (Biopredictive, Paris, France)

IFN= Interferon; e Cl Cr= estimated clearance creatinine